Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vittorio Del Fabro

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Frontiers in Oncology|April 17, 2023
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimabAndrea Duminuco, Alessandra Romano, Dario Leotta, et al.
Hematology Reports|September 23, 2024
IgG-k/IgG-λ Para-Osseous Plasmacytoma Relapsed as Soft-Tissue Plasmacytoma with IgA-k Immunophenotype: A Case Report and Review of the Literature on Related Biochemical AspectsManlio Fazio, Chiara Maria Catena Sorbello, Vittorio Del Fabro, et al.
European Journal of Haematology|January 5, 2011
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cellsCesarina Giallongo, Piera La Cava, Daniele Tibullo, et al.
Journal of Clinical Medicine|January 8, 2025
Emergencies in Hematology: Why, When and How I Treat?Andrea Duminuco, Vittorio Del Fabro, Paola De Luca, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic LandscapeAndrea Duminuco, Patrick Harrington, Vittorio Del Fabro, et al.
Cancers|August 26, 2023
Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life StudyVittorio Del Fabro, Mary Ann Di Giorgio, Valerio Leotta, et al.
Cancers|March 10, 2022
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 InfectionAlessandra Romano, Claudio Cerchione, Concetta Conticello, et al.
European Journal of Haematology|November 24, 2025
Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life StudyAndrea Duminuco, Vittorio Del Fabro, Gabriella Santuccio, et al.
Journal of Clinical Medicine|October 19, 2019
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsMarina Silvia Parisi, Salvatore Leotta, Alessandra Romano, et al.
Diseases (Basel, Switzerland)|February 26, 2026
Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients-A Survey from Two Italian CentersVittorio Del Fabro, Lara Gullo, Giuliana Giunta, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|April 17, 2023
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimabAndrea Duminuco, Alessandra Romano, Dario Leotta, et al.
Hematology Reports|September 23, 2024
IgG-k/IgG-λ Para-Osseous Plasmacytoma Relapsed as Soft-Tissue Plasmacytoma with IgA-k Immunophenotype: A Case Report and Review of the Literature on Related Biochemical AspectsManlio Fazio, Chiara Maria Catena Sorbello, Vittorio Del Fabro, et al.
European Journal of Haematology|January 5, 2011
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cellsCesarina Giallongo, Piera La Cava, Daniele Tibullo, et al.
Journal of Clinical Medicine|January 8, 2025
Emergencies in Hematology: Why, When and How I Treat?Andrea Duminuco, Vittorio Del Fabro, Paola De Luca, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic LandscapeAndrea Duminuco, Patrick Harrington, Vittorio Del Fabro, et al.
Cancers|August 26, 2023
Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life StudyVittorio Del Fabro, Mary Ann Di Giorgio, Valerio Leotta, et al.
Cancers|March 10, 2022
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 InfectionAlessandra Romano, Claudio Cerchione, Concetta Conticello, et al.
European Journal of Haematology|November 24, 2025
Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life StudyAndrea Duminuco, Vittorio Del Fabro, Gabriella Santuccio, et al.
Journal of Clinical Medicine|October 19, 2019
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsMarina Silvia Parisi, Salvatore Leotta, Alessandra Romano, et al.
Diseases (Basel, Switzerland)|February 26, 2026
Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients-A Survey from Two Italian CentersVittorio Del Fabro, Lara Gullo, Giuliana Giunta, et al.
Pageof 4